Pilot study of Mylotarg, idarubicin and cytarabine combination regimen in patients with primary resistant or relapsed acute myeloid leukemia

Yesid Alvarado, Apostolia Tsimberidou, Hagop Kantarjian, Jorge Cortes, Guillermo Garcia-Manero, Stefan Faderl, Deborah Thomas, Elihu Estey, Francis J. Giles

Research output: Contribution to journalArticlepeer-review

63 Scopus citations

Abstract

Purpose: Mylotarg has moderate activity as a single agent in patients with CD33-positive refractory or relapsed acute myelogenous leukemia (AML). A combination of an anthracycline and cytarabine (ara-C) is the core of most AML induction regimens. We conducted a pilot study of Mylotarg combined with idarubicin and ara-C in patients with refractory or relapsed AML. Methods: Mylotarg was administered at 6 mg/m2 intravenously on days 1 and 15, idarubicin 12 mg/m2 daily on days 2 through 4, and ara-C at 1.5 g/m2 daily on days 2 through 5 (MIA). Results: Of 14 patients were treated, 4 (29%) had primary resistant AML, and 10 (71%) relapsed AML. The median age of the patients was 61 years (range 34-74 years). MIA induced complete remission (CR) in three patients (21%) and CR with incomplete platelet recovery (CRp) in three patients (21%). The median survival was 8 weeks (range 2-64 weeks), and the median failure-free survival of CR patients was 27 weeks (range 11-64 weeks). All patients developed grade 3/4 myelosuppression - severe sepsis occurred in ten patients (71%). Other grade 3/4 nonhematologic toxicities included hepatic transaminitis, oral mucositis, and diarrhea. Two patients (14%) developed hepatic venoocclusive disease (VOD). Conclusions: The addition of Mylotarg to idarubicin and ara-C is feasible. MIA has significant activity in patients with refractory AML. Hepatotoxicity and VOD are significant toxicities of Mylotarg-based combinations.

Original languageEnglish (US)
Pages (from-to)87-90
Number of pages4
JournalCancer Chemotherapy and Pharmacology
Volume51
Issue number1
DOIs
StatePublished - Jan 16 2003
Externally publishedYes

Keywords

  • Acute myeloid leukemia
  • Cytarabine
  • Idarubicin
  • Mylotarg
  • Venoocclusive disease

ASJC Scopus subject areas

  • Oncology
  • Toxicology
  • Pharmacology
  • Cancer Research
  • Pharmacology (medical)

Fingerprint Dive into the research topics of 'Pilot study of Mylotarg, idarubicin and cytarabine combination regimen in patients with primary resistant or relapsed acute myeloid leukemia'. Together they form a unique fingerprint.

Cite this